Cargando…

Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report

Background: Amyotrophic lateral sclerosis (ALS) is one of the most frequently occurring neurodegenerative diseases affecting speech and swallowing. This preliminary study aimed to investigate whether an autologous lineage-negative stem/progenitor cell therapy applied to ALS patients affects the leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlukowska, Wioletta, Baumert, Bartłomiej, Gołąb-Janowska, Monika, Pius-Sadowska, Ewa, Litwińska, Zofia, Kotowski, Maciej, Meller, Agnieszka, Rotter, Iwona, Peregud-Pogorzelski, Jarosław, Nowacki, Przemysław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415387/
https://www.ncbi.nlm.nih.gov/pubmed/32788871
http://dx.doi.org/10.7150/ijms.47002
_version_ 1783569163519787008
author Pawlukowska, Wioletta
Baumert, Bartłomiej
Gołąb-Janowska, Monika
Pius-Sadowska, Ewa
Litwińska, Zofia
Kotowski, Maciej
Meller, Agnieszka
Rotter, Iwona
Peregud-Pogorzelski, Jarosław
Nowacki, Przemysław
author_facet Pawlukowska, Wioletta
Baumert, Bartłomiej
Gołąb-Janowska, Monika
Pius-Sadowska, Ewa
Litwińska, Zofia
Kotowski, Maciej
Meller, Agnieszka
Rotter, Iwona
Peregud-Pogorzelski, Jarosław
Nowacki, Przemysław
author_sort Pawlukowska, Wioletta
collection PubMed
description Background: Amyotrophic lateral sclerosis (ALS) is one of the most frequently occurring neurodegenerative diseases affecting speech and swallowing. This preliminary study aimed to investigate whether an autologous lineage-negative stem/progenitor cell therapy applied to ALS patients affects the level of selected trophic and proinflammatory factors, and subsequently improves the articulation. Methods: We enrolled 12 patients with sporadic ALS, who underwent autologous bone marrow-derived lineage negative (LIN(-)) cells administration into cerebrospinal fluid (CSF). We evaluated patients' articulation using the Frenchay Dysarthria Assessment on days 0 and 28 following the LIN(-) cells administration. Concentrations of various factors (BDNF, NGF, ANGP-2, VEGF, PDGF-AA, PEDF, COMP-FH, CRP, C3, C4) in CSF were quantified by multiplex fluorescent bead-based immunoassays in the samples collected on the day of LIN(-) cells administration and 28 days later. On top of this, we assessed levels of BDNF and NGF in the patients' plasma on the day of the injection, three, seven days and three months after the treatment. Results: Of the 12 patients who received the LIN(-) cell therapy 8 showed short-termed improvement in articulatory functions (group I), which was particularly noticeable in better phonation time, lips and soft palate performance, swallowing reflex and voice loudness. Four patients (group II) did not show substantial improvement. CSF concentrations of BDNF, ANGP-2 and PDGF-AA in group I decreased significantly 28 days after LIN(-) cells administration. The highest concentration levels of BDNF in group II and NGF in both groups in blood plasma were observed on day 3 following the injection. Conclusions: The outcomes of the LIN(-) cell application in ALS treatment of articulatory organs are promising. The procedure proved to be safe and feasible. A short-lasting trophic effect of autologous LIN(-) administration could encourage repeated cell's application in order to sustain their beneficial effects, however this approach needs further investigation.
format Online
Article
Text
id pubmed-7415387
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-74153872020-08-11 Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report Pawlukowska, Wioletta Baumert, Bartłomiej Gołąb-Janowska, Monika Pius-Sadowska, Ewa Litwińska, Zofia Kotowski, Maciej Meller, Agnieszka Rotter, Iwona Peregud-Pogorzelski, Jarosław Nowacki, Przemysław Int J Med Sci Research Paper Background: Amyotrophic lateral sclerosis (ALS) is one of the most frequently occurring neurodegenerative diseases affecting speech and swallowing. This preliminary study aimed to investigate whether an autologous lineage-negative stem/progenitor cell therapy applied to ALS patients affects the level of selected trophic and proinflammatory factors, and subsequently improves the articulation. Methods: We enrolled 12 patients with sporadic ALS, who underwent autologous bone marrow-derived lineage negative (LIN(-)) cells administration into cerebrospinal fluid (CSF). We evaluated patients' articulation using the Frenchay Dysarthria Assessment on days 0 and 28 following the LIN(-) cells administration. Concentrations of various factors (BDNF, NGF, ANGP-2, VEGF, PDGF-AA, PEDF, COMP-FH, CRP, C3, C4) in CSF were quantified by multiplex fluorescent bead-based immunoassays in the samples collected on the day of LIN(-) cells administration and 28 days later. On top of this, we assessed levels of BDNF and NGF in the patients' plasma on the day of the injection, three, seven days and three months after the treatment. Results: Of the 12 patients who received the LIN(-) cell therapy 8 showed short-termed improvement in articulatory functions (group I), which was particularly noticeable in better phonation time, lips and soft palate performance, swallowing reflex and voice loudness. Four patients (group II) did not show substantial improvement. CSF concentrations of BDNF, ANGP-2 and PDGF-AA in group I decreased significantly 28 days after LIN(-) cells administration. The highest concentration levels of BDNF in group II and NGF in both groups in blood plasma were observed on day 3 following the injection. Conclusions: The outcomes of the LIN(-) cell application in ALS treatment of articulatory organs are promising. The procedure proved to be safe and feasible. A short-lasting trophic effect of autologous LIN(-) administration could encourage repeated cell's application in order to sustain their beneficial effects, however this approach needs further investigation. Ivyspring International Publisher 2020-07-19 /pmc/articles/PMC7415387/ /pubmed/32788871 http://dx.doi.org/10.7150/ijms.47002 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Pawlukowska, Wioletta
Baumert, Bartłomiej
Gołąb-Janowska, Monika
Pius-Sadowska, Ewa
Litwińska, Zofia
Kotowski, Maciej
Meller, Agnieszka
Rotter, Iwona
Peregud-Pogorzelski, Jarosław
Nowacki, Przemysław
Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report
title Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report
title_full Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report
title_fullStr Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report
title_full_unstemmed Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report
title_short Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report
title_sort articulation recovery in als patients after lineage-negative adjuvant cell therapy - preliminary report
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415387/
https://www.ncbi.nlm.nih.gov/pubmed/32788871
http://dx.doi.org/10.7150/ijms.47002
work_keys_str_mv AT pawlukowskawioletta articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT baumertbartłomiej articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT gołabjanowskamonika articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT piussadowskaewa articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT litwinskazofia articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT kotowskimaciej articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT melleragnieszka articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT rotteriwona articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT peregudpogorzelskijarosław articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport
AT nowackiprzemysław articulationrecoveryinalspatientsafterlineagenegativeadjuvantcelltherapypreliminaryreport